Advertisement

Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for anti-non-small cell lung cancer activity

  • Qiang Feng
  • Hualong He
  • Tiantao Gao
  • Qiangsheng Zhang
  • Zhihao Liu
  • Xin Tao
  • Yongxia Zhu
  • Lidan Zhang
  • Luoting Yu
Original Article
  • 26 Downloads

Abstract

The histone lysine methyltransferase EZH2 has been reported to play important roles in cancer aggressiveness, metastasis and poor prognosis. In this study, a series of benzomorpholine derivatives were synthesized and biologically evaluated as EZH2 inhibitors. The target compounds were obtained in good yields from 3-amino-5-bromo-2-hydroxybenzoic acid via cyclization, Suzuki coupling and amidation as the key steps. A preliminary optimization study led to the discovery of several potent novel EZH2 inhibitors (6b, 6c, 6x and 6y). Moreover, 6y inhibited the A549 and NCI-H1975 cell lines (IC50 = 1.1 µM and 1.1 µM, respectively). Further studies indicated that 6y can reduce EZH2 expression in intact cells and cause cell arrest in the G2/M phase.

Keywords

EZH2 inhibitor Antiproliferation activity Benzomorpholine Structure–activity relationship 

Notes

Acknowledgements

We appreciate the funding support from the National Natural Science Foundation of China (No. 81602398) and the China Postdoctoral Science Foundation (Nos. 2015M582561, 2016T90861). We also thank Zhejiang Apeloa Medical Technology Co., Ltd, for financial support and Lihua Zhou of Key Laboratory of Biotherapy (Sichuan University) for NMR measurements.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68:7–30.  https://doi.org/10.3322/caac.21442 CrossRefPubMedGoogle Scholar
  2. 2.
    Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 4:605–644CrossRefGoogle Scholar
  3. 3.
    Reck M, Heigener DF, Mok T, Soria JC, Rabe KF (2013) Management of non-small-cell lung cancer: recent developments. Lancet 382:709–719.  https://doi.org/10.1016/s0140-6736(13)61502-0 CrossRefPubMedGoogle Scholar
  4. 4.
    Takara K, Sakaeda T, Okumura K (2006) An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12:273–286.  https://doi.org/10.2174/138161206775201965 CrossRefPubMedGoogle Scholar
  5. 5.
    Chen C, Chen JZ, Zhao KN (2014) Signalling pathways in anti-cancer drug resistance. Curr Med Chem 21:3007–3008.  https://doi.org/10.2174/092986732126140804160443 CrossRefPubMedGoogle Scholar
  6. 6.
    Wee S, Dhanak D, Li HT, Armstrong SA, Copeland RA, Sims R, Baylin SB, Liu XS, Schweizer L (2014) Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci 1309:30–36.  https://doi.org/10.1111/nyas.12356 CrossRefPubMedGoogle Scholar
  7. 7.
    Cao R, Wang LJ, Wang HB, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y (2002) Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 298:1039–1043.  https://doi.org/10.1126/science.1076997 CrossRefPubMedGoogle Scholar
  8. 8.
    Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D (2002) Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 16:2893–2905.  https://doi.org/10.1101/gad.1035902 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Margueron R, Reinberg D (2011) The polycomb complex PRC2 and its mark in life. Nature 469:343–349.  https://doi.org/10.1038/nature09784 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Tamgue O, Chai CS, Hao L, Zambe J-CD, Huang WW, Zhang B, Lei M, Wei YM (2013) Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells. Asian Pac J Cancer Prev 14:5663–5669.  https://doi.org/10.7314/APJCP.2013.14.10.5663 CrossRefPubMedGoogle Scholar
  11. 11.
    Li ZW, Wang YL, Qiu J, Li Q, Yuan CP, Zhang W, Wang DM, Ye JH, Jiang HB, Yang JR, Cheng J (2013) The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Onco Targets Ther 4:2532–2549.  https://doi.org/10.18632/oncotarget.1503 CrossRefGoogle Scholar
  12. 12.
    Kleer CG, Cao Q, Varambally S, Shen RL, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100:11606–11611.  https://doi.org/10.1073/pnas.1933744100 CrossRefPubMedGoogle Scholar
  13. 13.
    Wagener N, Macher-Goeppinger S, Pritsch M, Hüsing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp A, Hoppe-Seyler F, Hohenfellner M (2010) Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10:524.  https://doi.org/10.1186/1471-2407-10-524 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li LR, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DSB, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L (2012) A landscape of driver mutations in melanoma. Cell 150:251–263.  https://doi.org/10.1016/j.cell.2012.06.024 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629.  https://doi.org/10.1038/nature01075 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, Yap D, Humphries RK, Griffith OL, Shah S, Zhu H, Kimbara M, Shashkin P, Charlot JF, Tcherpakov M, Corbett R, Tam A, Varhol R, Smailus D, Moksa M, Zhao Y, Delaney A, Qian H, Birol I, Schein J, Moore R, Holt R, Horsman DE, Connors JM, Jones S, Aparicio S, Hirst M, Gascoyne RD, Marra MA (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42:181–185.  https://doi.org/10.1038/ng.518 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298–303.  https://doi.org/10.1038/nature10351 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Guo SP, Chan JKC, Iqbal J, McKeithan T, Fu K, Meng B, Pan Y, Cheuk W, Luo DL, Wang RA, Zhang WW, Greiner TC, Chan WC (2014) EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations. Clin Cancer Res 20:3078–3086.  https://doi.org/10.1158/1078-0432.ccr-13-1597 CrossRefPubMedGoogle Scholar
  19. 19.
    Qi W, Chan HM, Teng L, Li L, Chuai S, Zhang RP, Zeng J, Li M, Fan H, Lin Y, Gu J, Ardayfio O, Zhang JH, Yan XX, Fang JL, Mi Y, Zhang M, Zhou T, Feng G, Chen ZJ, Li GB, Yang T, Zhao KH, Liu XH, Yu ZT, Lu CX, Atadja P, Li E (2012) Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 109:21360–21365.  https://doi.org/10.1073/pnas.1210371110 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Glazer RI, Hartman KD, Knode MC, Richard MM, Chiang PK, Tseng CKH, Marquez VE (1986) 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun 135:688–694.  https://doi.org/10.1016/0006-291x(86)90048-3 CrossRefPubMedGoogle Scholar
  21. 21.
    Vaswani RG, Gehling VS, Dakin LA, Cook AS, Nasveschuk CG, Duplessis M, Iyer P, Balasubramanian S, Zhao F, Good AC, Campbell R, Lee C, Cantone N, Cummings RT, Normant E, Bellon SF, Albrecht BK, Harmange JC, Trojer P, Audia JE, Zhang Y, Justin N, Chen SY, Wilson JR, Gamblin SJ (2016) Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide(CPI-1205), a potent and selective inhibitor of histone methyltransferase EZH2, suitable for phase I clinical trials for B-Cell lymphomas. J Med Chem 59:9928–9941.  https://doi.org/10.1021/acs.jmedchem.6b01315 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Agulnik M, Tannir NM, Pressey JG, Gounder MM, Cote GM, Roche M, Doleman S, Blakemore SJ, Clawson A, Daigle S, Tang J, Ho PTC, Demetri GD (2016) A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma.  https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS11071
  23. 23.
    Gao TT, Zhang LD, Zhu YX, Song XJ, Feng Q, Lei Q, Shi SX, Deng HX, Xiong MH, You XY, Zuo WQ, Liu L, Peng CT, Wang NY, Ye TH, Xia Y, Yu LT (2016) ZLD1122, a novel EZH2 and EZH1 small molecular inhibitor, blocks H3K27 methylation and diffuse large B cell lymphoma cell growth. RSC Adv 6:28512–28521.  https://doi.org/10.1039/c6ra00618c CrossRefGoogle Scholar
  24. 24.
    Zhang LD, Song XJ, Wang NY, Zhao LF, Feng Q, You XY, Peng CT, Gao TT, Xiong MH, He B, Gao C, Luo Y, Xu Y, Zhang QY, Yu LT (2015) Design, synthesis and biological evaluation of novel 1-methyl-3-oxo-2,3,5,6,7,8-hexahydroisoquinolins as potential EZH2 inhibitors. RSC Adv 5:25967–25978.  https://doi.org/10.1039/c5ra02365c CrossRefGoogle Scholar
  25. 25.
    Song XJ, Gao TT, Wang NY, Feng Q, You XY, Ye TH, Lei Q, Zhu YX, Xiong MH, Xia Y, Yang FF, Shi YJ, Wei YQ, Zhang LD, Yu LT (2016) Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer. Sci Rep 6:20864–20876.  https://doi.org/10.1038/srep24893 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Simard JR, Plant MH, Emkey R, Yu V (2013) Development and implementation of a high-throughput AlphaLISA assay for identifying inhibitors of EZH2 methyltransferase. Assay Drug Dev Technol 11:152–162.  https://doi.org/10.1089/adt.2012.481 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Qiang Feng
    • 1
    • 2
  • Hualong He
    • 1
  • Tiantao Gao
    • 1
  • Qiangsheng Zhang
    • 1
  • Zhihao Liu
    • 1
  • Xin Tao
    • 1
  • Yongxia Zhu
    • 1
  • Lidan Zhang
    • 1
  • Luoting Yu
    • 1
  1. 1.Lab of Medicinal Chemistry, Cancer Center, West China HospitalSichuan University and Collaborative Innovation CenterChengduChina
  2. 2.College of Chemistry and Life ScienceChengdu Normal UniversityChengduChina

Personalised recommendations